Skip to main content
Caplight Logo









Karis Bio

Karis Bio

Private
SeoulHealthcare & Life Scienceshttps://karisbio.com/

Last Round

Series B

Dec 1, 2024

Total Funding Raised

$17.18M

Company Overview

Karis Bio is a biotechnology company that develops regenerative cell therapies using induced pluripotent stem cell (iPSC) technology to treat cardiovascular diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting, Data as a Service

AI Layer

Application

Keywords

regenerative medicineiPSC therapyinduced pluripotent stem cellcell therapycardiovascular diseaseautologous cell therapybiomanufacturingcGMP manufacturingautonomous biomanufacturingstem cell therapyvascular regenerationclinical-stage biotechCDMOcontract manufacturingbiotech startup

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Karis Bio Comparables

Compare Karis Bio with similar companies based on industry and business-model similarity.

Karis Bio comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Cuorips Inc.
77%
IPS HEART
75%
Bayer AG
69%

Karis Bio Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BDec 1, 2024
Series AMay 1, 2021
AngelDec 1, 2020

Karis Bio Investors

Notable investors and investment history

Karis Bio investors
InvestorRounds
Premier PartnersSeries B, Series A
Devsisters VenturesSeries B, Series A
Korea Development BankSeries B, Series A
Korea Venture Investment CorporationSeries B
AJU IB InvestmentSeries B, Series A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Dec 1, 2024

    $8M round with participation from Devsisters Ventures and Premier Partners.

  • Dec 1, 2020

    Completed an Angel funding round.

Karis Bio Filings

Explore SEC and related filing metadata, where available.

Karis Bio filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Karis Bio's valuation, stock price, and market status.

Is Karis Bio a public or private company?

Karis Bio is a private company.

What is the current stock price of Karis Bio?

Karis Bio is a private company with no public stock price. No recent secondary market data is available.

How much is Karis Bio worth (valuation)?

Valuation information for Karis Bio is not publicly available.

Can I buy Karis Bio stock?

Karis Bio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Karis Bio's last funding round?

Karis Bio's most recent funding round was Series B on December 1, 2024.

Who are the main investors in Karis Bio?

Key investors in Karis Bio include Premier Partners, Devsisters Ventures, Korea Development Bank, Korea Venture Investment Corporation, AJU IB Investment.

Will Karis Bio IPO soon?

No public IPO plans have been announced for Karis Bio.

How can I track Karis Bio secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Karis Bio's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersSeoul
Year Founded2020
Last FundingDec 1, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?